Page last updated: 2024-09-04
docetaxel anhydrous and oxadiazoles
docetaxel anhydrous has been researched along with oxadiazoles in 1 studies
Compound Research Comparison
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (oxadiazoles) | Trials (oxadiazoles) | Recent Studies (post-2010) (oxadiazoles) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 6,057 | 257 | 2,359 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Cui, Q; Dai, M; Dong, Z; Huang, C; Josephraj, S; Kyei-Baffour, K; Liu, JY; Peery, R; Zhang, JT | 1 |
Other Studies
1 other study(ies) available for docetaxel anhydrous and oxadiazoles
Article | Year |
---|---|
A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Dimerization; Docetaxel; Humans; Hydrazones; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Oxadiazoles; Prodrugs; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Survivin | 2022 |